Frost & Sullivan Independent Equity Research
Oramed Pharmaceuticals Inc.: Sufficient funds for clinical development activity over the next 24 months; several clinical milestones are scheduled for 2018 and 2019; as Oramed’s clinical progress meets our expectations, stock target price remains at NIS 53.2.
Company: Oramed Pharmaceuticals Inc.
Report type: Update for the quarter ending 31 May 2018
Published on: 24 July, 2018